SRRK · Scholar Rock Holding Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | $33.19M | $18.82M | $15.40M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $208.44M | $184.55M | $121.90M | $124.44M | $108.47M | $74.06M |
| SG&A | $176.21M | $67.50M | $49.40M | $43.12M | $40.27M | $28.22M |
| Total Operating Expenses | $384.64M | $252.05M | $171.29M | $167.56M | $148.74M | $102.28M |
| D&A | $1.66M | $1.94M | $2.84M | $2.99M | $2.63M | $1.49M |
| Operating Income | ($384.64M) | ($252.05M) | ($171.29M) | ($134.37M) | ($129.92M) | ($86.88M) |
| Interest Expense | $6.30M | $6.60M | $6.50M | $4.70M | $2.10M | $400.0K |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($377.94M) | ($246.29M) | ($165.79M) | ($134.50M) | ($131.80M) | ($86.48M) |
| EPS - Basic | ($3.29) | ($2.47) | ($1.99) | ($2.26) | ($2.81) | - |
| EPS - Diluted | ($3.29) | ($2.47) | ($1.99) | ($2.26) | ($2.81) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $323.53M | $177.88M | $101.86M | $103.28M | $212.84M | $160.36M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $10.30M | $10.10M | $3.46M | $3.99M | $4.43M | $3.41M |
| Current Assets | $385.15M | $451.17M | $288.19M | $328.02M | $265.32M | $344.40M |
| Total Assets | $404.27M | $474.92M | $311.04M | $358.17M | $304.44M | $388.31M |
| Current Liabilities | $55.42M | $46.94M | $32.74M | $36.39M | $64.30M | $42.56M |
| Long-term Debt | $99.71M | $50.15M | $48.68M | $49.74M | $48.42M | $24.68M |
| Total Liabilities | $158.78M | $106.29M | $85.82M | $97.93M | $132.37M | $127.53M |
| Stockholders' Equity | $245.49M | $368.63M | $225.22M | $260.24M | $172.07M | $260.77M |
| Retained Earnings | ($1.30B) | ($922.72M) | ($676.42M) | ($510.63M) | ($376.13M) | ($244.33M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($300.04M) | ($200.95M) | ($145.23M) | ($132.69M) | ($126.79M) | ($60.27M) |
| Investing Cash Flow | $218.69M | ($76.06M) | $41.14M | ($171.70M) | $134.31M | ($63.50M) |
| Financing Cash Flow | $228.40M | $353.03M | $102.57M | $194.83M | $44.95M | $247.82M |
| CapEx | $602.0K | $98.0K | $71.0K | $1.06M | $5.25M | $4.09M |
| Free Cash Flow | ($300.64M) | ($201.05M) | ($145.30M) | ($133.76M) | ($132.04M) | ($64.36M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | -404.8% | -690.5% | -564.0% |
| EBITDA margin | - | - | - | -395.8% | -676.5% | -554.4% |
| Net margin | - | - | - | -405.2% | -700.5% | -561.5% |
| Free cash flow margin | - | - | - | -403.0% | -701.7% | -417.8% |
| FCF / Net income | 0.80 | 0.82 | 0.88 | 0.99 | 1.00 | 0.74 |
| R&D / Revenue | - | - | - | 374.9% | 576.5% | 480.8% |
| SG&A / Revenue | - | - | - | 129.9% | 214.0% | 183.2% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -93.5% | -51.9% | -53.3% | -37.6% | -43.3% | -22.3% |
| Return on equity | -154.0% | -66.8% | -73.6% | -51.7% | -76.6% | -33.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 6.95 | 9.61 | 8.80 | 9.01 | 4.13 | 8.09 |
| Quick ratio | 6.95 | 9.61 | 8.80 | 9.01 | 4.13 | 8.09 |
| Cash ratio | 5.84 | 3.79 | 3.11 | 2.84 | 3.31 | 3.77 |
| Leverage | ||||||
| Debt / Equity | 0.41 | 0.14 | 0.22 | 0.19 | 0.28 | 0.09 |
| Debt / Assets | 0.25 | 0.11 | 0.16 | 0.14 | 0.16 | 0.06 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -61.1x | -38.2x | -26.4x | -28.6x | -61.9x | -217.2x |
| Equity multiplier | 1.65 | 1.29 | 1.38 | 1.38 | 1.77 | 1.49 |
| Liabilities / Assets | 0.39 | 0.22 | 0.28 | 0.27 | 0.43 | 0.33 |
| Efficiency | ||||||
| Asset turnover | 0.00 | - | - | 0.09 | 0.06 | 0.04 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 20.6x | 11.7x | 7.0x | 2.1x | 4.4x | - |
| P / S | - | - | - | 16.3x | 40.6x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | 76.4% | 22.2% | -24.8% |
| Revenue CAGR (3y) | - | - | - | 17.4% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -52.6% | -47.1% | -27.5% | -3.4% | -49.5% | -59.3% |
| Net income growth (YoY) | -53.5% | -48.6% | -23.3% | -2.1% | -52.4% | -69.6% |
| EPS growth (YoY) | -33.2% | -24.1% | 11.9% | 19.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -49.5% | -38.4% | -8.6% | -1.3% | -105.2% | 2.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -33.4% | 63.7% | -13.5% | 51.2% | -34.0% | 131.0% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-4.45
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Scholar Rock Holding Corp against the 5 most active filers in the same SIC group.